8,291 Shares in Thermo Fisher Scientific Inc. $TMO Acquired by Pinnbrook Capital Management LP

Key Points

• Pinnbrook Capital Management opened a new position in Thermo Fisher Scientific, buying 8,291 shares valued at about $4.8 million in the fourth quarter.
• Thermo Fisher reported better-than-expected quarterly results, with EPS of $5.44 versus estimates of $5.25 and revenue of $11.01 billion, up 6.2% year over year.
• The company declared a quarterly dividend of $0.47 per share, and analysts currently rate TMO a Moderate Buy with an average price target of $616.10.

Pinnbrook Capital Management LP bought a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 8,291 shares of the medical research company's stock, valued at approximately $4,804,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. High Note Wealth LLC raised its stake in Thermo Fisher Scientific by 170.6% during the 4th quarter. High Note Wealth LLC now owns 46 shares of the medical research company's stock worth $27,000 after acquiring an additional 29 shares during the period. JPL Wealth Management LLC bought a new stake in Thermo Fisher Scientific during the 3rd quarter worth approximately $28,000. Beacon Financial Strategies CORP bought a new stake in Thermo Fisher Scientific during the 4th quarter worth approximately $29,000. Olistico Wealth LLC bought a new stake in Thermo Fisher Scientific during the 4th quarter worth approximately $29,000. Finally, Cloud Capital Management LLC bought a new stake in Thermo Fisher Scientific during the 3rd quarter worth approximately $31,000. Institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Trading Down 0.5%

TMO stock opened at $449.43 on Friday. The firm has a fifty day moving average price of $481.20 and a 200 day moving average price of $538.80. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $643.99. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.15 and a current ratio of 1.53. The firm has a market cap of $167.02 billion, a PE ratio of 24.71, a price-to-earnings-growth ratio of 2.00 and a beta of 0.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share for the quarter, beating analysts' consensus estimates of $5.25 by $0.19. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The firm had revenue of $11.01 billion during the quarter, compared to analyst estimates of $10.86 billion. During the same period last year, the firm posted $5.15 earnings per share. Thermo Fisher Scientific's revenue for the quarter was up 6.2% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. Sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 24.86 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 15th. Shareholders of record on Monday, June 15th will be paid a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a yield of 0.4%. The ex-dividend date of this dividend is Monday, June 15th. Thermo Fisher Scientific's payout ratio is presently 10.34%.

Wall Street Analyst Weigh In

A number of research firms have commented on TMO. TD Cowen decreased their target price on shares of Thermo Fisher Scientific from $696.00 to $683.00 and set a "buy" rating on the stock in a research note on Friday, January 30th. Robert W. Baird reduced their price objective on shares of Thermo Fisher Scientific from $653.00 to $639.00 and set an "outperform" rating on the stock in a research report on Friday, April 24th. Citigroup lifted their price objective on shares of Thermo Fisher Scientific from $660.00 to $685.00 and gave the company a "buy" rating in a research report on Friday, January 30th. Jefferies Financial Group upgraded shares of Thermo Fisher Scientific to a "strong-buy" rating in a research report on Friday, April 24th. Finally, Wells Fargo & Company reduced their price objective on shares of Thermo Fisher Scientific from $675.00 to $615.00 and set an "overweight" rating on the stock in a research report on Friday, May 8th. Two analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, Thermo Fisher Scientific currently has a consensus rating of "Moderate Buy" and an average price target of $616.10.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction on Monday, April 27th. The shares were sold at an average price of $462.66, for a total transaction of $185,064.00. Following the completion of the transaction, the chief operating officer directly owned 25,051 shares of the company's stock, valued at $11,590,095.66. The trade was a 1.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc N. Casper sold 5,000 shares of Thermo Fisher Scientific stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the transaction, the chief executive officer directly owned 123,925 shares of the company's stock, valued at $63,499,170. The trade was a 3.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.33% of the stock is owned by insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.